Compare Nucor Corporation (NUE) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nucor Corporation vs Sana Biotechnology Inc — how do they compare? Nucor Corporation trades at $250.92 (market cap $55.84B), while Sana Biotechnology Inc trades at $2.81 (market cap $836.71M). The key difference: Nucor Corporation is far larger — about 66.7× Sana Biotechnology Inc's market cap, and Nucor Corporation pays a 0.91% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nucor Corporation for 78 Days and Sana Biotechnology Inc for 23 Days on average.
| NUE | SANA | |
|---|---|---|
Market Cap | $55.84B | $836.71M |
Volume | 848,835 | 4,507,444 |
Sector | Basic Materials | Health |
52-Week High | $274.74 | $5.92 |
52-Week Low | $131.78 | $2.68 |
Typical Hold Time | 78 Days | 23 Days |
Enterprise Value | $60.25B | $749.96M |
Dividend Yield | 0.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nucor (NUE) trades at $250.98, up 1.84% on the day, showing resilience amid a mixed technical backdrop. Recent earnings have beaten expectations in Q1 and Q2 2026, though Q4 2025 was a miss. The company maintains a strong balance sheet with a debt-to-asset ratio of 20.23% for 2025, and analyst consensus is a Moderate Buy with a $266.88 price target. Revenue is projected to grow to $36.1B in 2026, with net income margin improving to 7.98%.
The outlook for NUE is cautiously optimistic, supported by earnings beats and a solid dividend history, but risks include competitive pressures from new steel capacity and volatile steel prices. The stock's current valuation metrics, such as a P/E of 19.64, appear reasonable relative to historical performance, offering potential upside if earnings guidance is met.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
